Research & Development
NICE backs Janssen's Tremfya for NHS use
11 May 2018 -

The National Institute for Health and Care Excellence (NICE) has recommended Janssen's Tremfya as a cost-effective treatment for plaque psoriasis, Pharma Times reported on Friday.

A Final Appraisal Determination was published by the cost regulator to back the funding for the drug, which was launched in the UK in the November.

Tremfya (guselkumab) is the first biologic to selectively target interleukin (IL)-23, a key protein involved in the immune inflammatory response in psoriasis.

The Final Appraisal Determination was fast-tracked as a result of the European approval in November last year. Approval was based on Phase III trials, VOYAGE 1 and VOYAGE 2, which showed high rates of skin clearance.

Janssen has agreed a confidential patient access scheme with the Department of Health and Social Care, offering the drug to the NHS at a reduced cost.

Login
Username:

Password:


Related Headlines

CStone passes US FDA IND approval for PD-L1 antibody, CS1001

Alphamab Oncology announces US FDA approval for cancer therapy KN026

Cellenkos to launch phase I clinical trial of CK0801 in patients with Guillain-Barré Syndrome (GBS) following US FDA clearance

AstraZeneca and Merck announce grant of Orphan Drug Designation by US FDA for pancreatic cancer medicine Lynparza

Allergan plc & Medicines360 partnership wins US FDA approval of sNDA for duration extension of contraceptive LILETTA

Applied DNA Subsidiary LineaRx Licenses CAR T Drug Candidate and Initiates Pre-Clinical Development of Non-Viral, Plasmid-Free CAR T Manufacturing Platform

Alnylam to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran

Peptilogics Receives Australian Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206

Reflexion Health's first randomised controlled trial in virtual physical therapy excels against traditional approach

MaaT Pharma doses first patient in phase two clinical trial of MaaT013

Mereo BioPharma Group completes patient enrolment for phase 2b clinical trial of BPS-804

CIVCO Radiotherapy passes US FDA 510k clearance and CE mark for Solstice SRS Immobilization System

X4 Pharmaceuticals Receives Orphan Drug Designation from the US FDA for X4P-001-RD for the Treatment of WHIM Syndrome

First Patient Dosed in Phase 2 Study of Karuna's Lead Product Candidate KarXT for the Treatment of Schizophrenia

Dr. Reddy's Laboratories Receives Approval for Aspirin and Extended-Release Dipyridamole Capsules in the US Market